Please use this identifier to cite or link to this item: https://doi.org/10.1021/acs.biomac.7b01176
Title: EXOPLEXs: Chimeric Drug Delivery Platform from the Fusion of Cell-Derived Nanovesicles and Liposomes
Authors: Goh W.J.
Zou S.
Lee C.K.
Ou Y.-H.
Wang J.-W. 
Czarny B.
Pastorin G.
Issue Date: 8-Jan-2018
Publisher: American Chemical Society
Citation: Goh W.J., Zou S., Lee C.K., Ou Y.-H., Wang J.-W., Czarny B., Pastorin G. (2018-01-08). EXOPLEXs: Chimeric Drug Delivery Platform from the Fusion of Cell-Derived Nanovesicles and Liposomes. Biomacromolecules 19 (1) : 22-30. ScholarBank@NUS Repository. https://doi.org/10.1021/acs.biomac.7b01176
Abstract: Cell-derived nanovesicles (CDNs) have been recently investigated as novel drug delivery systems (DDSs), due to the preservation of key features from the cell membrane of their precursor cells, which are responsible for an efficient cellular uptake by target cells. However, CDNs suffer from low drug loading efficiencies as well as challenges in functionalization compared to conventional DDS like liposomes. Here, we describe the first study proposing the fusion of CDNs with liposomes to form EXOPLEXs. We report the preservation of cell membranes from precursor cells similarly to CDNs, as well as high loading efficiencies of more than 65% with doxorubicin hydrochloride, a model chemotherapeutic drug. The doxorubicin-loaded EXOPLEXs (DOX-EXO) also demonstrated a higher in vitro cell killing effect than liposomes, while EXOPLEXs alone did not show any remarkable cytotoxicity. Taken together, these results illustrate the potential of EXOPLEXs as a novel DDS for targeted delivery of chemotherapeutics. � 2017 American Chemical Society.
Source Title: Biomacromolecules
URI: http://scholarbank.nus.edu.sg/handle/10635/146747
ISSN: 15257797
DOI: 10.1021/acs.biomac.7b01176
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.